SCHEMBL6505294

SCHEMBL6505294

Cc1ccc(C(C=O)c2cccnc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
CFTR P13569 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
GOPC Q9HD26 1/20 0.42
CYP19A1 P11511 2/20 0.41
GAA P10253 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2A6 P11509 1/20 0.40
TBXAS1 P24557 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NAMPT P43490 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.38
KCNN4 O15554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360712 0.86 CFTR (0.57) ALDH1A1CFTRSLC6A2SLC6A4SLC6A3
SCHEMBL6501548 0.85 CFTR (0.41) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL3903975 0.84 CYP11B1 (0.44) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL6502611 0.83 POLB (0.51) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL6503338 0.83 CYP19A1 (0.62) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL6498870 0.83 ALDH1A1 (0.49) ALDH1A1CFTRSLC6A2SLC6A4SLC6A3
SCHEMBL6498908 0.83 KMT2A (0.46) ALDH1A1CYP19A1CYP3A4SMN1; SMN2NPC1
SCHEMBL8191216 0.81 PTGS2 (0.48) ALDH1A1CYP3A4L3MBTL1NAMPT
SCHEMBL6504970 0.80 CYP19A1 (0.39) SLC6A2SLC6A4SLC6A3CYP19A1GAA
SCHEMBL1515700 0.80 LMNA (0.46) ALDH1A1SLC6A3CYP2A6SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 ALDH1A1 3345/4885CFTR 3911/4885SLC6A2 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.